Will Soghikian

Douglas Miehm

James Vane-Tempest

Vishwesh Shah

Olivia Brayer

Yu He (Arthur)

Joseph Schwartz

Maurice Raycroft

Stacy Ku

Arthur He

David Martin

Ed Arce

Farzin Haque

Sahil Dhingra

- Aurinia Pharmaceuticals reported **Q3 2025 total revenue of $73.5 million**, an 8% increase from Q3 2024, and **LUPKYNIS net product sales of $70.6 million**, up 27% year-over-year.  **[0001600620_2231068_1]** 
- The company raised its **2025 total revenue guidance to $275 million-$280 million** and **LUPKYNIS sales guidance to $265 million-$270 million** for the second time this year.  **[0001600620_2231068_0]** **[0001600620_2231068_1]** 
- **Net income for Q3 2025 increased by 119% to $31.6 million**, with diluted EPS rising **130% to $0.23**.  **[0001600620_2231068_1]** 
- Aurinia is advancing its **Atenercept program** into clinical studies for two autoimmune diseases by the end of 2025, following positive Phase 1 results.  **[0001600620_2231068_0]** **[0001600620_2231068_2]** 
- For the nine months ended September 30, 2025, the company repurchased **$98.2 million in shares**, reducing diluted shares outstanding from 149.8 million to 138.2 million.  **[0001600620_2231068_1]**

Aurinia Pharmaceuticals Reports Strong Q3 2025 Results and Raises Full-Year Guidance

- Aurinia Pharmaceuticals reported **Q3 2025 total revenue** of **$73.5 million**, an **8% increase** from Q3 2024, driven by **LUPKYNIS net product sales** of **$70.6 million**, up **27%**.  **[1600620_0001600620-25-000108_exhibit991_q32025earningsr.htm:0]** **[1600620_0001600620-25-000108_thirdquarter2025updatede.htm:0]** 
- **Net income** for Q3 2025 surged **119%** to **$31.6 million**, resulting in **diluted earnings per share** of **$0.23**, a **130% increase** year-over-year.  **[1600620_0001600620-25-000108_exhibit991_q32025earningsr.htm:0]** **[1600620_0001600620-25-000108_thirdquarter2025updatede.htm:0]** 
- The company **raised its full-year 2025 total revenue guidance** to a range of **$275 million to $280 million** and **net product sales guidance** to **$265 million to $270 million**.  **[1600620_0001600620-25-000108_exhibit991_q32025earningsr.htm:0]** 
- As of September 30, 2025, Aurinia maintained a strong cash position with **$351.8 million** in cash, cash equivalents, restricted cash, and investments.  **[1600620_0001600620-25-000108_exhibit991_q32025earningsr.htm:0]** **[1600620_0001600620-25-000108_thirdquarter2025updatede.htm:0]** 
- Aurinia repurchased **12.2 million** common shares for **$98.2 million** during the nine months ended September 30, 2025, and is advancing aritinercept towards clinical studies in two autoimmune diseases by year-end.  **[1600620_0001600620-25-000108_exhibit991_q32025earningsr.htm:0]** **[1600620_0001600620-25-000108_thirdquarter2025updatede.htm:0]**

- Aurinia Pharmaceuticals reported **net income** of **$31.6 million** for the third quarter of 2025, a **119% increase** year-over-year, and **$76.4 million** for the nine months ended September 30, 2025, a **1677% increase**.  **[1600620_6d84cecf84e34678b642de6dfdb30dfd_0]** 
- **Total revenue** for Q3 2025 was **$73.5 million** and **$205.9 million** for the nine months, with **LUPKYNIS net product sales** growing **27%** to **$70.6 million** in Q3 2025.  **[1600620_6d84cecf84e34678b642de6dfdb30dfd_0]** 
- The company **raised its full-year 2025 guidance**, projecting total revenue between **$275 million and $280 million** and net product sales between **$265 million and $270 million**.  **[1600620_6d84cecf84e34678b642de6dfdb30dfd_1]** 
- As of September 30, 2025, Aurinia held **$351.8 million** in cash, cash equivalents, restricted cash, and investments, and repurchased **12.2 million** common shares for **$98.2 million** during the first nine months of 2025.  **[1600620_6d84cecf84e34678b642de6dfdb30dfd_0]**

Aurinia Pharmaceuticals Reports Q3 and Nine-Month 2025 Financial Results and Raises Full-Year Guidance

Aurinia Pharmaceuticals (AUPH)